Study Highlights Link Between ART and Weight Gain in Virally Suppressed Participants
March 7th 2019A study reports that weight gain in individuals on ART was associated with lower BMI, reduced proportion of hypogonadism, increased proportion of psychiatric disorders, and non-PI-containing regimens.
Read More
The Botswana Beat Cohort Study: Favorable Outcomes for Dolutegravir-Based Regimens
March 7th 2019Investigators report 12-month outcomes from the Botswana Epidemiological ART Treatment Cohort Study (BEAT), an observational research cohort tracking virologic and clinical outcomes of people living with HIV who are beginning dolutegravir-based regimens.
Read More
DISCOVER Study: HIV Incidence Rates Low in MSM and Transgender Women Taking F/TAF or F/TDF for PrEP
March 7th 2019HIV incidence rates in MSM and transgender women taking F/TAF or F/TDF were found to be very low and significantly less than the rate in at-risk individuals not on PrEP in the US.
Read More
Bictegravir/FTC/TAF Single-Tablet Regimen Well-Tolerated in Children and Adolescents
March 6th 2019Following FDA approval of a single-tablet bictegravir, emtricitabine, and tenofovir alafenamide regimen for use in adults with HIV, investigators are exploring the safety and efficacy of the same therapy in children and adolescents aged 6 to 18 years.
Read More
Viral Load Decline Achieved Faster in Pregnant Women Treated with Raltegravir
March 5th 2019A trial comparing raltegravir with efavirenz for antiretroviral therapy in treatment naïve pregnant women with HIV supports the use of raltegravir, especially for women starting ART later in gestation.
Read More
Ending the HIV Epidemic in the US: Why Now Is the Right Time
March 5th 2019Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, has been fighting HIV/AIDS since the 1980s when the virus was first discovered. Now, thanks to a joint effort by multiple arms of the US Department of Health and Human Services, he’s making headway.
Read More